Determination of the socially oriented role of pharmacists in the prevention, diagnosis and treatment of patients with viral hepatitis

Authors

DOI:

https://doi.org/10.15587/2519-4852.2024.314295

Keywords:

viral hepatitis, diagnosis, role of pharmacist, pharmaceutical information service, pharmaceutical care

Abstract

Viral hepatitis (VH) is one of the most significant medical and social problems worldwide, posing a global threat to public health.

The aim of the study was to determine the socially oriented role of pharmacists in the prevention, diagnosis and treatment of patients with VH, in particular in the implementation of decentralization of VH diagnostic services in Ukraine.

The study was based on statistical reports of the WHO, the Public Health Centre of the Ministry of Health of Ukraine, international WHO guidelines on the diagnosis and pharmacotherapy of viral hepatitis, and scientific publications.

Results of the study. Taking into account the results of the analysis of world experience and based on the WHO Concept in cooperation with FIP ‘Seven Star Pharmacist’ and its modern interpretation, we have identified the current role of pharmacists in the prevention, diagnosis and treatment of patients with VH.

Based on the recommendations of the WHO and the Ministry of Health of Ukraine, which define the pharmacist as a link in the support of pharmacotherapy for patients with VH, a model of information and advisory pharmaceutical service is proposed, which provides for the involvement of resources of the state and regional levels at the stages of need assessment, planning and control of the service, resources of health care facilities and pharmacies, and the stages of planning and implementation of the pharmaceutical service.

Noting the successful international experience and peculiarities of modern pharmaceutical care provided to patients with hypertension, we propose an adapted model of patient-pharmacist-physician interaction. This model is based on the fact that the pharmacist is one of the professional implementers of the state policy on providing the population of Ukraine with medicines and medical devices, and through the implementation of interaction with the patient and the doctor, based on the basic principles we have developed.

Thus, the analysis of approaches to defining the socially oriented role of pharmacists in the prevention, diagnosis and treatment of patients with hypertension has become the basis for the development of models for the provision of information and advisory pharmaceutical services and a model of patient-pharmacist-physician interaction.

Conclusions. The implementation of the model of information and advisory pharmaceutical service and the model of patient-pharmacist-physician interaction in practice will facilitate the timely detection of threatening symptoms of a socially dangerous disease and, accordingly, the diagnosis of potential VH patients and their visit to a doctor and, as a result, will be a way to prevent irrational self-medication and ensure timely, economically justified pharmacotherapy for this category of patients

Author Biographies

Alla Kotvitska, National University of Pharmacy

Doctor of Pharmaceutical Sciences, Professor, Acting rector

Alina Volkova, National University of Pharmacy

PhD, Associate Professor, Head of Department

Department of Social Pharmacy

Almira Nozdrina, National University of Pharmacy

PhD, Assistant

Department of Social Pharmacy

Iryna Surikova, National University of Pharmacy

PhD, Associate Professor

Department of Social Pharmacy

References

  1. Consolidated guidelines on person-centred viral hepatitis strategic information: using data to support country scale-up of hepatitis prevention, diagnosis and treatment services (2024). WHO. Available at: https://www.who.int/publications/i/item/9789240091313
  2. Viral hepatitis B and C policies in countries and burden of disease in WHO regions (2023). WHO. Available at: https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/hepatitis-factsheet_2023.pdf?sfvrsn=fd9e78cf_5
  3. Progress report on HIV, viral hepatitis and sexually transmitted infections. Accountability for the global health sector strategies, 2016–2021 (2019). Geneva: World Health Organization. Available at: https://www.who.int/publications/i/item/progress-report-on-hiv-viral-hepatitis-and-sexually-transmitted-infections-2019
  4. WHO Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection (2015). WHO. Available at: https://www.who.int/publications/i/item/9789241549059
  5. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030 (2020). WHO. Available at: https://iris.who.int/bitstream/handle/10665/360348/9789240053779-eng.pdf?sequence=1
  6. WHO guidelines on hepatitis B and C testing (2017). WHO. Available at: https://iris.who.int/bitstream/handle/10665/254621/9789241549981-eng.pdf?sequence=1&isAllowed=y
  7. Recommendations and guidance on hepatitis C virus self-testing (2021). Geneva: World Health Organization. Available at: https://iris.who.int/bitstream/handle/10665/342803/9789240031128-eng.pdf?sequence=1
  8. Hayes, M. J., Beavon, E., Traeger, M. W., Dillon, J. F., Radley, A., Nielsen, S. et al. (2024). Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysis. EClinicalMedicine, 69, 102489. https://doi.org/10.1016/j.eclinm.2024.102489
  9. Gauld, N., Perry, J., Jackson, C. (2020). Feasibility and outcomes of a hepatitis C screening programme in community pharmacies. The New Zealand Medical Journal, 133, 74–83.
  10. Marino, E. L., Alvarez-Rubio, L., Miro, S., Modamio, P., Banos, F., Lastra, C. F., Alberdi-Leniz, A. (2009). Pharmacist Intervention in Treatment of Patients With Genotype 1 Chronic Hepatitis C. Journal of Managed Care Pharmacy, 15 (2), 147–150. https://doi.org/10.18553/jmcp.2009.15.2.147
  11. Briggs, A. L. (2018). Pharmacists’ increasing involvement in hepatitis C management and prevention. Journal of the American Pharmacists Association, 58 (1), 5–6. https://doi.org/10.1016/j.japh.2017.12.008
  12. Kugelmas, M., Pedicone, L., Lio, I. (2017). Hepatitis C Point-of-Care Screening in Retail Pharmacies in the United States. Gastroenterology & Hepatology, 13 (2), 98–104.
  13. Isho, N. Y., Kachlic, M. D., Marcelo, J. C., Martin, M. T. (2017). Pharmacist-initiated hepatitis C virus screening in a community pharmacy to increase awareness and link to care at the medical center. Journal of the American Pharmacists Association, 57 (3), S259–S264. https://doi.org/10.1016/j.japh.2017.03.006
  14. Adee, M., Zhuo, Y., Zhong, H., Zhan, T., Aggarwal, R., Shilton, S., Chhatwal, J. (2021). Assessing cost-effectiveness of hepatitis C testing pathways in Georgia using the Hep C Testing Calculator. Scientific Reports, 11 (1). https://doi.org/10.1038/s41598-021-00362-y
  15. Radley, A., de Bruin, M., Inglis, S. K., Donnan, P. T., Hapca, A., Barclay, S. T. et al. (2020). Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. The Lancet Gastroenterology & Hepatology, 5 (9), 809–818. https://doi.org/10.1016/s2468-1253(20)30120-5
  16. Global hepatitis report 2024: action for access in low- and middle-income countries (2024). WHO, 242. Available at: https://www.who.int/publications/i/item/9789240091672
  17. Informational materials about viral hepatitis of the PHC. Available at: https://phc.org.ua/kontrol-zakhvoryuvan/virusni-gepatiti/informaciyni-materiali-pro-vg
  18. Ghany, M. G., Morgan, T. R. (2020). Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology, 71 (2), 686–721. https://doi.org/10.1002/hep.31060
  19. WHO Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C infection. Geneva: World Health Organization, 2019.
  20. Stämpfli, D., Imfeld-Isenegger, T. L., Hersberger, K. E., Messerli, M. (2023). Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot. BMC Infectious Diseases, 23 (1). https://doi.org/10.1186/s12879-023-08362-1
  21. Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low– and middle–income countries (2021). Geneva: World Health Organization. Available at: https://iris.who.int/bitstream/handle/10665/338901/9789240019003-eng.pdf
  22. Bruck, W., Вaladad, С. (2022). Pharmacists Can Identify, Prevent, and Treat Viral Hepatitis. Pharmacy times health-system edition, 11 (3), 21–23.
  23. Dong, B. J., Lopez, M., Cocohoba, J. (2017). Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project. Journal of the American Pharmacists Association, 57 (4), 510-515.e2. https://doi.org/10.1016/j.japh.2017.04.463
  24. Sebhatu, P., Martin, M. T. (2016). Genotype 1 hepatitis C virus and the pharmacist’s role in treatment. American Journal of Health-System Pharmacy, 73 (11), 764–774. https://doi.org/10.2146/ajhp150704
  25. Langness, J. A., Nguyen, M., Wieland, A., Everson, G. T., Kiser, J. J. (2017). Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World Journal of Gastroenterology, 23 (9), 1618–1626. https://doi.org/10.3748/wjg.v23.i9.1618
  26. Koren, D. E., Zuckerman, A., Teply, R., Nabulsi, N. A., Lee, T. A., Martin, M. T. (2019). Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist–Driven Model. Open Forum Infectious Diseases, 6 (7). https://doi.org/10.1093/ofid/ofz316
  27. Ledezma Morales, M., Salazar-Ospina, A., Amariles, P., Hincapié-García, J. A. (2020). Rol del farmacéutico en la atención integral de pacientes con hepatitis C: revisión sistemática. Revista Colombiana de Gastroenterología, 35 (4), 485–505. https://doi.org/10.22516/25007440.510
  28. Zaepfel, M., Cristofaro, L., Trawinski, A., McCarthy, K., Rightmier, E., Khadem, T. (2016). Evaluation of a Hepatitis C Patient Management Program at a University Specialty Pharmacy. Annals of Pharmacotherapy, 51 (4), 307–314. https://doi.org/10.1177/1060028016683495
  29. Gomes, L. O., Teixeira, M. R., Rosa, J. A. da, Foppa, A. A., Rover, M. R. M., Farias, M. R. (2020). The benefits of a public pharmacist service in chronic hepatitis C treatment: The real-life results of sofosbuvir-based therapy. Research in Social and Administrative Pharmacy, 16 (1), 48–53. https://doi.org/10.1016/j.sapharm.2019.02.008
  30. Hunt, B. R., Cetrone, H., Sam, S., Glick, N. R. (2021). Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment Program in an Urban Safety-Net Health System, Chicago, 2017-2019. Public Health Reports, 137(4), 702–710. https://doi.org/10.1177/00333549211015664
  31. Kherghehpoush, S., McKeirnan, K. C. (2021). Pharmacist-led HIV and hepatitis C point-of-care testing and risk mitigation counseling in individuals experiencing homelessness. Exploratory Research in Clinical and Social Pharmacy, 1, 100007. https://doi.org/10.1016/j.rcsop.2021.100007
  32. Volkova, A. V., Nozdrina, A. A. (2023). Analysis of the awareness by healthcare professionals and the public about viral hepatitis in the context of decentralisation of diagnostics. Farmatsevtychnyi Zhurnal, 5, 20–33. https://doi.org/10.32352/0367-3057.5.23.03
  33. Nozdrina, A., Volkova, A., Cherkashyna, A., Ovakimian, O. (2022). Results of analysis of epidemological indicators of viral hepatitis c in regions of the world as part of activities to improve pharmaceutical provision for patients. ScienceRise: Pharmaceutical Science, 2 (36), 72–80. https://doi.org/10.15587/2519-4852.2022.255858
  34. Kotvitska, A., Volkova, A., Korzh, I., Surikova, I. (2021). Comparative analysis of indicators that determine the effectiveness of the implementation of socio-economic determinants of health in Europe and Ukraine. ScienceRise: Pharmaceutical Science, 3 (31), 34–41. https://doi.org/10.15587/2519-4852.2021.235787
Determination of the socially oriented role of pharmacists in the prevention, diagnosis and treatment of patients with viral hepatitis

Downloads

Published

2024-10-31

How to Cite

Kotvitska, A., Volkova, A., Nozdrina, A., & Surikova, I. (2024). Determination of the socially oriented role of pharmacists in the prevention, diagnosis and treatment of patients with viral hepatitis. ScienceRise: Pharmaceutical Science, (5 (51), 104–112. https://doi.org/10.15587/2519-4852.2024.314295

Issue

No. 5 (51) (2024)

Section

Pharmaceutical Science

License

Copyright (c) 2024 Alla Kotvitska, Alina Volkova, Almira Nozdrina, Iryna Surikova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.